News

July 18, 2015 10:45 am
Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an...
July 17, 2015 11:45 pm
Takeda has filed for FDA approval of ixazomib, which could become the first oral proteasome inhibitor for treating multiple myeloma. The New Drug Application (NDA) for ixazomib is based on the results of the phase III TOURMALINE-MM1 trial, which...
July 17, 2015 10:30 am
In his blog this week, IMF Chairman Dr. Brian Durie examines a new study in the July 2015 issue of “Cancer Epidemiology, Biomarkers & Prevention” suggesting that women who spend more leisure time sitting may be at a higher risk for multiple...
July 10, 2015 10:30 am
Having myeloma is undeniably expensive. But will new systems of evaluating the cost and efficacy of treatment end up harming myeloma patients by mandating suboptimal care and eliminating access to needed drugs? In his blog this week, IMF Chairman...

Pages